Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Budde, Lihua E ^a,b,c   Berger, Carolina ^b   Lin, Yukang ^b   Wang, Jinjuan ^b   Lin, Xubin ^b   Frayo, Shani E ^b   Brouns, Shaunda A ^b   Spencer, David M ^d,e   Till, Brian G ^b,c   Jensen, Michael C ^b,f   Riddell, Stanley R ^b,c,g   Press, Oliver W ^b,c  

^a City of Hope ^*  (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e Bellicum Pharmaceuticals   (United States)

^f SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; CD137 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD20 CHIMERIC ANTIGEN RECEPTOR; CD28 ANTIGEN; LENTIVIRUS VECTOR; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CELL EXPANSION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; GENE ACTIVATION; GENE SWITCHING; GENE TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE TRANSFUSION; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; SUICIDE GENE; T LYMPHOCYTE; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD20; CASPASE 9; CELLS, CULTURED; GENES, TRANSGENIC, SUICIDE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; JURKAT CELLS; LYMPHOMA; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; NIH 3T3 CELLS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893127616     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082742     Document Type: Article

References (38)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29. doi:10.3322/caac.20138.
2. Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, et al. (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118: 4817-4828. doi:10.1182/blood-2011-04-348540.
3. Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733. doi:10.1056/NEJMoa1103849.
4. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, et al. (2011) T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. Science Translational Medicine 3: 95ra73-95ra73. doi:10.1126/scitranslmed.3002842.
5. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, et al. (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119: 2709-2720. doi:10.1182/blood-2011-10-384388.
6. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, et al. (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12: 6106-6115. doi:10.1158/1078-0432.CCR-06-1183.
7. Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, et al. (2007) Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 15: 825-833. doi:10.1038/sj.mt.6300104.
8. Lamers CHJ, Sleijfer S, Vulto AG, Kruit WHJ, Kliffen M, et al. (2006) Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience. JCO 24: e20-e22. doi:10.1200/JCO.2006.05.9964.
9. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, et al. (2008) Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112: 2261-2271. doi:10.1182/blood-2007-12-128843.
10. Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 20: 70-75. doi:10.1038/nbt0102-70.
11. Finney HM, Akbar AN, Lawson ADG (2004) Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 172: 104-113.
12. Friedmann-Morvinski D, Bendavid A, Waks T, Schindler D, Eshhar Z (2005) Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood 105: 3087-3093. doi:10.1182/blood-2004-09-3737.
13. Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, et al. (2009) A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 183: 5563-5574. doi:10.4049/jimmunol.0900447.
14. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, et al. (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121: 1822-1826. doi:10.1172/JCI46110.
15. Wang J, Jensen M, Lin Y, Sui X, Chen E, et al. (2007) Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 18: 712-725. doi:10.1089/hum.2007.028.
16. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, et al. (2009) Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 106: 3360-3365. doi:10.1073/pnas.0813101106.
17. Zhong X-S, Matsushita M, Plotkin J, Riviere I, Sadelain M (2010) Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell-mediated Tumor Eradication. Molecular Therapy 18: 413-420. doi:10.1038/mt.2009.210.
18. Till BG, Jensen MC, Wang J, Qian X, Gopal AK, et al. (2012) CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119: 3940-3950. doi:10.1182/blood-2011-10-387969.
19. Check E (2002) A tragic setback. Nature 420: 116-118. doi:10.1038/420116a.
20. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, et al. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419. doi:10.1126/science.1088547.
21. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M (2010) Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 18: 666-668. doi:10.1038/mt.2010.31.
22. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, et al. (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18: 843-851. doi:10.1038/mt.2010.24.
23. Fan L, Freeman KW, Khan T, Pham E, Spencer DM (1999) Improved artificial death switches based on caspases and FADD. Hum Gene Ther 10: 2273-2285. doi:10.1089/10430349950016924.
24. Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, et al. (2010) Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24: 1160-1170. doi:10.1038/leu.2010.75.
25. Di Stasi A, Tey S-K, Dotti G, Fujita Y, Kennedy-Nasser A, et al. (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365: 1673-1683. doi:10.1056/NEJMoa1106152.
26. Gerull S, Beard BC, Peterson LJ, Neff T, Kiem H-P (2007) In vivo selection and chemoprotection after drug resistance gene therapy in a nonmyeloablative allogeneic transplantation setting in dogs. Hum Gene Ther 18: 451-456. doi:10.1089/hum.2006.039.
27. Shan D, Press OW, Tsu TT, Hayden MS, Ledbetter JA (1999) Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths. J Immunol 162: 6589-6595.
28. Zhou LJ, Ord DC, Hughes AL, Tedder TF (1991) Structure and domain organization of the CD19 antigen of human, mouse, and guinea pig B lymphocytes. Conservation of the extensive cytoplasmic domain. J Immunol 147: 1424-1432.
29. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, et al. (2004) Correction of multi-gene deficiency in vivo using a single "self- cleaving" 2A peptide-based retroviral vector. Nat Biotechnol 22: 589-594. doi:10.1038/nbt957.
30. Becker PS, Taylor JA, Trobridge GD, Zhao X, Beard BC, et al. (2010) Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector. Gene Ther 17: 1244-1252. doi:10.1038/gt.2010.62.
31. James SE, Orgun NN, Tedder TF, Shlomchik MJ, Jensen MC, et al. (2009) Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice. Blood 114: 5454-5463. doi:10.1182/blood-2009- 08-232967.
32. Berger C, Blau CA, Huang M-L, Iuliucci JD, Dalgarno DC, et al. (2004) Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood 103: 1261-1269. doi:10.1182/blood-2003-08- 2908.
33. Straathof KC, Pulè MA, Yotnda P, Dotti G, Vanin EF, et al. (2005) An inducible caspase 9 safety switch for T-cell therapy. Blood 105: 4247-4254. doi:10.1182/blood-2004-11-4564.
34. Tey S-K, Dotti G, Rooney CM, Heslop HE, Brenner MK (2007) Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 13: 913-924. doi:10.1016/j.bbmt.2007.04.005.
35. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, et al. (2008) Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 118: 294-305. doi:10.1172/JCI32103.
36. Wang X, Berger C, Wong CW, Forman SJ, Riddell SR, et al. (2011) Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood 117: 1888-1898. doi:10.1182/blood-2010-10-310599.
37. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, et al. (2009) Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo. Mol Ther 17: 1453-1464. doi:10.1038/mt.2009.83.
38. Iuliucci JD, Oliver SD, Morley S, Ward C, Ward J, et al. (2001) Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J Clin Pharmacol 41: 870-879.